» Articles » PMID: 28424555

HMGB1 is Negatively Correlated with the Development of Endometrial Carcinoma and Prevents Cancer Cell Invasion and Metastasis by Inhibiting the Process of Epithelial-to-mesenchymal Transition

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2017 Apr 21
PMID 28424555
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

High-mobility group box protein 1 (HMGB1), a nuclear protein that plays a significant role in DNA architecture and transcription, was correlated with the progression of some types of cancer. However, the role of HMGB1 in endometrial cancer cell invasion and metastasis remains unexplored. HMGB1 expression was initially assessed by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in normal endometrial tissue and endometrial carcinoma tissue. High expressions of HMGB1 protein were detected in normal endometrial tissues; however, in endometrial cancer tissues, the expressions of HMGB1 were found to be very weak. Furthermore, HMGB1 expressions were negatively correlated with advanced stage and lymph node metastasis in endometrial cancer. Then by RT-qPCR, Western blot and immunocytochemistry, HMGB1 was also detected in primary cultured endometrial cells and four kinds of endometrial cancer cell lines (Ishikawa, HEC-1A, HEC-1B and KLE). We found that the expression of HMGB1 was much higher in normal endometrial cells than in endometrial cancer cells, and reduced expression levels of HMGB1 were observed especially in the highly metastatic cell lines. Using lentivirus transfection, HMGB1 small hairpin RNA was constructed, and this infected the lowly invasive endometrial cancer cell lines, Ishikawa and HEC-1B. HMGB1 knockdown significantly enhanced the proliferation, invasion and metastasis of endometrial cancer cells and induced the process of epithelial-to-mesenchymal transition. These results can contribute to the development of a new potential therapeutic target for endometrial cancer.

Citing Articles

Role of Receptor for Advanced Glycation End-Products in Endometrial Cancer: A Review.

Zglejc-Waszak K, Jozwik M, Thoene M, Wojtkiewicz J Cancers (Basel). 2024; 16(18).

PMID: 39335163 PMC: 11430655. DOI: 10.3390/cancers16183192.


Function of as a competing endogenous RNA to promote progression in gastric cancer by regulating the axis.

Qin J, Zhen S, Wang J, Lv W, Zhao Y, Duan Y J Gastrointest Oncol. 2023; 14(3):1259-1278.

PMID: 37435216 PMC: 10331750. DOI: 10.21037/jgo-23-240.


Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.

Ga H, Taguchi A, Honjoh H, Nishijima A, Eguchi S, Miyamoto Y Arch Gynecol Obstet. 2023; 308(5):1629-1634.

PMID: 37310452 PMC: 10520125. DOI: 10.1007/s00404-023-07077-7.


Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer.

Zheng X, Wang X, He Y, Ge H Front Mol Biosci. 2022; 9:844618.

PMID: 35923467 PMC: 9340210. DOI: 10.3389/fmolb.2022.844618.


circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.

Yu Y, Dong G, Li Z, Zheng Y, Shi Z, Wang G Int J Oncol. 2022; 60(4).

PMID: 35211755 PMC: 8878724. DOI: 10.3892/ijo.2022.5328.


References
1.
Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P . Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med. 2016; 5(9):2350-8. PMC: 5055166. DOI: 10.1002/cam4.827. View

2.
Ostberg T, Kawane K, Nagata S, Yang H, Chavan S, Klevenvall L . Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum. 2010; 62(10):2963-72. DOI: 10.1002/art.27590. View

3.
Leclerc E, Sturchler E, Vetter S, Heizmann C . Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci. 2009; 20(2):95-110. DOI: 10.1515/revneuro.2009.20.2.95. View

4.
Jin C, Liang R . miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells. J Obstet Gynaecol Res. 2015; 41(10):1653-60. DOI: 10.1111/jog.12756. View

5.
Bakkum-Gamez J, Mariani A, Dowdy S, Weaver A, McGree M, Martin J . Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy. Gynecol Oncol. 2014; 132(3):578-84. PMC: 4310003. DOI: 10.1016/j.ygyno.2014.01.007. View